Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)

NCT07560410 is registered in ClinicalTrials.gov with China Medical University Hospital as lead sponsor.

NCT NCT07560410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07560410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)
Lead sponsor
China Medical University Hospital
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
May 15, 2026
Completion date
April 14, 2029
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone cancer